Cargando…
Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia
BACKGROUND: Chronic Helicobacter pylori infection may induce gastric intestinal metaplasia (IM). We compared anti-H. pylori antibody profiles between IM cases and non-atrophic gastritis (NAG) controls. METHODS: We evaluated humoral responses to 1528 H. pylori proteins among a discovery set of 50 IM...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610335/ https://www.ncbi.nlm.nih.gov/pubmed/36301365 http://dx.doi.org/10.1007/s00535-022-01933-0 |
_version_ | 1784819243610537984 |
---|---|
author | Song, Lusheng Song, Minkyo Rabkin, Charles S. Chung, Yunro Williams, Stacy Torres, Javier Corvalan, Alejandro H. Gonzalez, Robinson Bellolio, Enrique Shome, Mahasish LaBaer, Joshua Qiu, Ji Camargo, M. Constanza |
author_facet | Song, Lusheng Song, Minkyo Rabkin, Charles S. Chung, Yunro Williams, Stacy Torres, Javier Corvalan, Alejandro H. Gonzalez, Robinson Bellolio, Enrique Shome, Mahasish LaBaer, Joshua Qiu, Ji Camargo, M. Constanza |
author_sort | Song, Lusheng |
collection | PubMed |
description | BACKGROUND: Chronic Helicobacter pylori infection may induce gastric intestinal metaplasia (IM). We compared anti-H. pylori antibody profiles between IM cases and non-atrophic gastritis (NAG) controls. METHODS: We evaluated humoral responses to 1528 H. pylori proteins among a discovery set of 50 IM and 50 NAG using H. pylori protein arrays. Antibodies with ≥ 20% sensitivity at 90% specificity for either group were selected and further validated in an independent set of 100 IM and 100 NAG using odds ratios (OR). A validated multi-signature was evaluated using the area under the receiver operating characteristics curve (AUC) and net reclassification improvement (NRI). RESULTS: Sixty-two immunoglobulin (Ig) G and 11 IgA antibodies were detected in > 10%. Among them, 22 IgG and 6 IgA antibodies were different between IM and NAG in the discovery set. Validated antibodies included 11 IgG (anti-HP1177/Omp27/HopQ [OR = 8.1, p < 0.001], anti-HP0547/CagA [4.6, p < 0.001], anti-HP0596/Tipα [4.0, p = 0.002], anti-HP0103/TlpB [3.8, p = 0.001], anti-HP1125/PalA/Omp18 [3.1, p = 0.001], anti-HP0153/RecA [0.48, p = 0.03], anti-HP0385 [0.41, p = 0.006], anti-HP0243/TlpB [0.39, p = 0.016], anti-HP0371/FabE [0.37, p = 0.017], anti-HP0900/HypB/AccB [0.35, p = 0.048], and anti-HP0709 [0.30, p = 0.003]), and 2 IgA (anti-HP1125/PalA/Omp18 [2.7, p = 0.03] and anti-HP0596/Tipα [2.5, p = 0.027]). A model including all 11 IgG antibodies (AUC = 0.81) had better discriminated IM and NAG compared with an anti-CagA only (AUC = 0.77) model (NRI = 0.44; p = 0.001). CONCLUSIONS: Our study represents the most comprehensive assessment of anti-H. pylori antibody profiles in IM. The target antigens for these novel antibodies may act together with CagA in the progression to IM. Along with other biomarkers, specific H. pylori antibodies may identify IM patients, who would benefit from surveillance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00535-022-01933-0. |
format | Online Article Text |
id | pubmed-9610335 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-96103352022-10-28 Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia Song, Lusheng Song, Minkyo Rabkin, Charles S. Chung, Yunro Williams, Stacy Torres, Javier Corvalan, Alejandro H. Gonzalez, Robinson Bellolio, Enrique Shome, Mahasish LaBaer, Joshua Qiu, Ji Camargo, M. Constanza J Gastroenterol Original Article—Alimentary Tract BACKGROUND: Chronic Helicobacter pylori infection may induce gastric intestinal metaplasia (IM). We compared anti-H. pylori antibody profiles between IM cases and non-atrophic gastritis (NAG) controls. METHODS: We evaluated humoral responses to 1528 H. pylori proteins among a discovery set of 50 IM and 50 NAG using H. pylori protein arrays. Antibodies with ≥ 20% sensitivity at 90% specificity for either group were selected and further validated in an independent set of 100 IM and 100 NAG using odds ratios (OR). A validated multi-signature was evaluated using the area under the receiver operating characteristics curve (AUC) and net reclassification improvement (NRI). RESULTS: Sixty-two immunoglobulin (Ig) G and 11 IgA antibodies were detected in > 10%. Among them, 22 IgG and 6 IgA antibodies were different between IM and NAG in the discovery set. Validated antibodies included 11 IgG (anti-HP1177/Omp27/HopQ [OR = 8.1, p < 0.001], anti-HP0547/CagA [4.6, p < 0.001], anti-HP0596/Tipα [4.0, p = 0.002], anti-HP0103/TlpB [3.8, p = 0.001], anti-HP1125/PalA/Omp18 [3.1, p = 0.001], anti-HP0153/RecA [0.48, p = 0.03], anti-HP0385 [0.41, p = 0.006], anti-HP0243/TlpB [0.39, p = 0.016], anti-HP0371/FabE [0.37, p = 0.017], anti-HP0900/HypB/AccB [0.35, p = 0.048], and anti-HP0709 [0.30, p = 0.003]), and 2 IgA (anti-HP1125/PalA/Omp18 [2.7, p = 0.03] and anti-HP0596/Tipα [2.5, p = 0.027]). A model including all 11 IgG antibodies (AUC = 0.81) had better discriminated IM and NAG compared with an anti-CagA only (AUC = 0.77) model (NRI = 0.44; p = 0.001). CONCLUSIONS: Our study represents the most comprehensive assessment of anti-H. pylori antibody profiles in IM. The target antigens for these novel antibodies may act together with CagA in the progression to IM. Along with other biomarkers, specific H. pylori antibodies may identify IM patients, who would benefit from surveillance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00535-022-01933-0. Springer Nature Singapore 2022-10-27 2023 /pmc/articles/PMC9610335/ /pubmed/36301365 http://dx.doi.org/10.1007/s00535-022-01933-0 Text en © Japanese Society of Gastroenterology 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article—Alimentary Tract Song, Lusheng Song, Minkyo Rabkin, Charles S. Chung, Yunro Williams, Stacy Torres, Javier Corvalan, Alejandro H. Gonzalez, Robinson Bellolio, Enrique Shome, Mahasish LaBaer, Joshua Qiu, Ji Camargo, M. Constanza Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia |
title | Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia |
title_full | Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia |
title_fullStr | Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia |
title_full_unstemmed | Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia |
title_short | Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia |
title_sort | identification of anti-helicobacter pylori antibody signatures in gastric intestinal metaplasia |
topic | Original Article—Alimentary Tract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610335/ https://www.ncbi.nlm.nih.gov/pubmed/36301365 http://dx.doi.org/10.1007/s00535-022-01933-0 |
work_keys_str_mv | AT songlusheng identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia AT songminkyo identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia AT rabkincharless identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia AT chungyunro identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia AT williamsstacy identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia AT torresjavier identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia AT corvalanalejandroh identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia AT gonzalezrobinson identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia AT bellolioenrique identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia AT shomemahasish identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia AT labaerjoshua identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia AT qiuji identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia AT camargomconstanza identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia |